NCT06927466View on ClinicalTrials.gov

A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.

PHASE1RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

September 19, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

June 30, 2028

Conditions
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Interventions
BIOLOGICAL

B019

B019： Intravenous infusion, 1.0×10\^6 CAR T cell/kg-10.0×10\^6 CAR T cell/kg

Trial Locations (8)

Unknown

RECRUITING

Peking University People's Hospital, Beijing

RECRUITING

Jiangxi Province pediatric hospital, Nanchang

RECRUITING

The First Affiliated Hospital of Nanchang University, Nanchang

RECRUITING

Children's Hospital of Shanghai, Shanghai

RECRUITING

Shanghai Children's Medical Center, Shanghai

RECRUITING

Children's Hospital of Soochow University, Suzhou

RECRUITING

Tongji Hospital, Wuhan

RECRUITING

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

All Listed Sponsors
lead

Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.

INDUSTRY